Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

NCT05096845 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

22500

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL: Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
OTHER: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

Sponsor

Livzon Pharmaceutical Group Inc.